Skip to Content

Triclabendazole use while Breastfeeding

Drugs containing Triclabendazole: Egaten

Medically reviewed by Drugs.com. Last updated on Sep 19, 2020.

Triclabendazole Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the use of triclabendazole during breastfeeding. Because of protein binding of 96% to 99% for the drug and metabolites, exposure of the breastfed infant is likely to be low.

Drug Levels

Triclabendazole is metabolized into its active sulfoxide metabolite, which is further metabolized to the active sulfone metabolite. These drugs have half-lives of 8, 14, and 11 hours, respectively. Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Triclabendazole

CAS Registry Number

68786-66-3

Drug Class

  • Breastfeeding
  • Lactation
  • Anti-Infective Agents
  • Antiparasitic Agents
  • Antiplatyhelmintic Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.